

AMENDMENTS TO THE CLAIMS

1. **(Currently Amended)** ~~Use A method for the treatment of a tumor, which comprises administering to a patient in need of such treatment and effective amount of active dendritic cells (DCs) releasing interleukin 12 (IL-12) which are loaded with an antigen against a specific tumor and, due to the treatment with lipopolysaccharide (L P S) and interferon-gamma (IFN- γ), release IL-12, for the preparation of a medicament for treating a patient having said specific tumor.~~
2. **(Currently Amended)** ~~Use The method~~ according to claim 1, characterised in that ~~wherein~~ said treatments is performed after bone marrow transplantation.
3. **(Currently Amended)** ~~Use The method~~ according to claim 1, characterised in that ~~wherein~~ said specific tumor is an advanced malignancy.
4. **(Currently Amended)** ~~Use The method~~ according to claim 1, characterised in that in ~~wherein~~ said DCs are DCs having been taken from the patient having said specific tumor or from the bone marrow donor.
5. **(Currently Amended)** ~~Use The method~~ according to claim 1, characterised in that ~~wherein~~ the DCs have been loaded with an antigen from a tumor cell from said patient having said specific tumor.
6. **(Currently Amended)** ~~Use The method~~ according to claim 5, characterised in, that ~~wherein~~ the DCs are additionally charged with a tracer antigen.
7. **(Currently Amended)** ~~Use The method~~ according to claim 6, characterised in that ~~wherein~~ said tracer antigen is keyhole limpet hemocyanine (KLH).
8. **(Currently Amended)** ~~Use The method~~ according to claim 7, characterised in that ~~wherein~~ the DCs are additionally charged with an adjuvant, especially with tetanus toxoid.

9. **(Currently Amended)** ~~Use The method according to claim 1, characterised in that wherein the DCs have been generated in vitro from peripheral blood mononuclear cells (PBMCs).~~
10. **(Currently Amended)** ~~Composition A composition for triggering IL-12 release from DCs containing which comprises LPS, IFN- γ and a tumor antigen.~~
11. **(Currently Amended)** ~~Composition The composition according to claim 10, characterised in that it wherein the composition is calf-serum free.~~
12. **(Currently Amended)** ~~Use A method for triggering IL-12 release from dendritic cells (DCs) which comprises administering to a patient an effective amount of a combination of LPS, IFN- γ and a tumor antigen for triggering IL-12 release from DCs.~~
13. **(Currently Amended)** ~~Use The method according to claim 12, characterised in that wherein the DCs have been loaded with an antigen from a tumor cell from a patient having said tumor.~~
14. **(Original)** Kit for triggering IL-12 release from DCs comprising
- LPS,
 - IFN- γ and
 - a tumor antigen.
15. **(Currently Amended)** ~~Use of a kit according to claim 14~~ A method for for triggering IL-12 release from dendritic cells (DCs) which comprises exposing DCs to the kit of claim 14.
16. **(Currently Amended)** ~~Use The method according to claim 15, characterised in that wherein the DCs have been loaded with an antigen from a tumor cell from a patient having said a tumor.~~